Preclinical evaluation of anti-restenotic therapies and drug-
eluting stents : efficacy and safety considerations
Pires, Nuno Miguel Marques
Citation
Pires, N. M. M. (2007, March 22). Preclinical evaluation of anti-restenotic therapies and drug-eluting stents : efficacy and safety considerations.
Department of Cardiology, Faculty of Medicine / Leiden University Medical Center (LUMC), Leiden University. Retrieved from
https://hdl.handle.net/1887/11455
Version: Not Applicable (or Unknown) License:
Downloaded from: https://hdl.handle.net/1887/11455
Note: To cite this publication please use the final published version (if applicable).
Preclinical evaluation of anti-restenotic therapies
and drug-eluting stents
Efficacy and safety considerations
Preclinical evaluation of anti-restenotic therapies
and drug-eluting stents
Efficacy and safety considerations
PROEFSCHRIFT
ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van de Rector Magnificus prof.mr. P.F. van der Heijden, volgens besluit van het College voor Promoties
te verdedigen op donderdag 22 maart 2007 klokke 16.15 uur
door
Nuno Miguel Marques Pires geboren te Santarém (Portugal)
in 1980
Promotiecommissie
Promotores: Prof. dr. J.W. Jukema
Prof. dr. P.H.A. Quax
Referent: Prof. dr. V.W.M. van Hinsbergh
(Vrije Universiteit Amsterdam)
Overige commissieleden: Prof. dr. M.J.A.P. Daemen (Universiteit Maastricht) Prof. dr. rer. nat. J.W. Fischer
(Heinrich-Heine-Universität Düsseldorf) Prof. dr. W.J. van der Giessen
(Erasmus Universiteit Rotterdam) Dr. B.J.M. van Vlijmen
Dr. C.J.M. de Vries
(Universiteit van Amsterdam)
The research described in this thesis was performed at the Gaubius Laboratory TNO-Quality of Life, Leiden, The Netherlands.
The study described in this thesis was supported by a grant of the Netherlands Heart Foundation (NHF-2001T032).
“The essence of knowledge is, having it, to apply it”
Confucius (551-479 BC)
Aos meus pais Para a Tai
Colofon
© 2007 N.M.M. Pires, Leiden, The Netherlands.
All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopy, record- ing, or any information storage and retrieval system, without permission from the copyright owner.
ISBN: 978-90-9021298-2
Cover design: M.R. de Vries & R.P.N. Tesselaar
Printed by: Gildeprint B.V. te Enschede, The Netherlands
The publication of this thesis has been kindly supported by:
Astellas Pharma B.V.
B. Braun Medical B.V.
Bayer B.V. HealthCare Boehringer Ingelheim B.V.
Bristol-Myers Squibb B.V.
Eli Lilly Critical Care Europe Jacques H. de Jong Stichring J.E. Jurriaanse Stichting
Medtronic Trading Nederland B.V.
Merck Sharp & Dohme B.V.
Pfizer B.V.
sanofi-aventis Netherlands B.V.
Servier Nederland Farma B.V.
Toshiba Medical Systems Nederland
Table of Contents
Chapter 1 9
Introduction
Chapter 2 21
Drug-eluting stents: results, promises and problems.
Int J Cardiol 2005;99:9-17
Chapter 3 39
Drug-eluting stents studies in mice: do we need atherosclerosis to study restenosis?
Vascul Pharmacol 2006;44:257-264
Chapter 4 55
Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(ε- caprolactone) stent cuff.
Biomaterials 2005;26:5386-5394
Chapter 5 73
Histopathologic alterations following local delivery of dexamethasone to inhibit restenosis in murine arteries.
Cardiovasc Res 2005;68:415-424
Chapter 6 91
Sirolimus and paclitaxel provoke different vascular pathological responses after local delivery in a murine model for restenosis on underlying atherosclerotic arter- ies.
Submitted for publication
Chapter 7 107
Genetic inflammatory factors predict restenosis after percutaneous coronary inter- ventions.
Adapted from Circulation 2005;112:2417-2425
Chapter 8 129
Tumor necrosis factor-alpha plays an important role in restenosis development.
FASEB J 2005;19:1998-2004
Chapter 9 147 Inhibition of neointima formation by local delivery of estrogen receptor alpha and beta specific agonists.
Cardiovasc Res 2007;73:217-226
Chapter 10 167
Activation of nuclear orphan receptor Nur77 by 6-mercaptopurine protects against restenosis.
Circulation 2007;115:493-500
Chapter 11 187
Local cre-mediated gene recombination in vascular smooth muscle cells in mice.
Transgenic Res 2006;15:31-36 Chapter 12
Summary and conclusions 199
Samenvatting en conclusies 207
Sumário e conclusões 215
List of Publications 223 Curriculum Vitae 227 Color supplement 229
